Liver Testing Through a New Investigative Tool
Function Matters
HepQuant: A minimally invasive assessment of chronic liver disease
New Investigative Tools to Evaluate the Liver
assessment of chronic liver disease
Novel technology for minimally invasive
Liver Function Tests
Breaking Through Conventional Thinking About Liver Health Testing
HepQuant is a privately-held, early-stage medical diagnostics company with unique, patented and patent-pending technology for assessing liver function of patients with chronic liver disease. HepQuant technologies, licensed from the University of Colorado Denver (UCD), have been advanced with the intent to profoundly impact the liver disease landscape – including the research, treatment and patient communities – with diagnostic products that are accurate and minimally invasive.
Recent Publications
- HepQuant SHUNT Detects Portal Hypertension in Early Stages of Clinically Compensated Chronic Liver Disease | Amanda Wieland, Ohad Etzion, Rabab O Ali, Elliot Levy, David E Kleiner, Steve M Helmke, Theo Heller, Gregory T Everson | Clin Gastroenterol Hepatol | 2021 Apr 22
- Predicting clinical decompensation in patients with cirrhosis using the Hepquant‐SHUNT test | Mohammad Amin Fallahzadeh Daniel J. Hansen James F. Trotter Gregory T. Everson Giovanna Saracino Robert S. Rahimi Steve Helmke Jodi Boutte Sumeet K. Asrani | Alimentary Pharmacology and Therapeutics | Feb. 8, 2021
- The within-individual reproducibility of the disease severity index from the HepQuant SHUNT test of liver function and physiology. Burton JR Jr, Helmke S, Lauriski S, Kittelson J, Everson GT. | Jan. 2, 2021
NASH Summit 2019
Upcoming Events
HepQuant will be attending / presenting at the following local, national or international meetings:
EASL International Liver Congress | June 23-26, Abstract Submission Pending
Recent Events
2021 AASLD/FDA DILI Conference Drug Induced Liver Injury | Virtual Conference | April 20 – 22, 2021 | “New Developments, Innovative Tools and Assessment Strategies in Patients with Underlying Liver Disease or Cancer and in the Setting of the Covid-19 Pandemic” | Gregory T. Everson, MD, FAASLD presented “Non-invasive Quantitative Liver Tests for Disease Activity and Fibrosis: Can They Reliably Guide Optimal Treatment Regimens During the Progression of CLD.”
- Poster: The Disease Severity Index (DSI) from the HepQuant SHUNT Test Sets the Stage for Predicting Drug Pharmacokinetics (PK) in Chronic Liver Disease
2021 NASH TAG Conference | March 11-13, 2021 | Attended by Gregory T. Everson, MD and Brad Everson, CBDO
AASLD: The Liver Meeting Digital Experience | November 13-16, 2020 | Conference Website
- Poster: The HepQuant SHUNT Test of Global Liver Function and Physiology Identifies the Patients with Advanced Fibrosis or Compensated Cirrhosis Who are At-Risk for Hepatocellular Carcinoma
- Poster: Diagnostic Performance of The HepQuant Shunt Test in Prediction of Large Esophageal Varices in Well-Compensated Fibrosis or Cirrhosis Due to Chronic Hep C
Oral Presentation by Baylor – AASLD: The Liver Meeting Digital Experience | November 13-16, 2020
- Presentation: “Dual Cholate Test and Prediction of Decompensation, Liver Transplantation, Death and Hospitalization in Cirrhosis: A Prospective Study.
HepQuant CEO Greg Everson joined Proactive at the Biotech Showcase 2020 in San Francisco, Jan. 14th, 2020.
CONTACT US
These images and links are for informational purposes only and do not imply that HepQuant has any formal relationships with the organizations, nor do the organizations endorse HepQuant or its liver function tests.